☆ 4.5 Letter

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

DERMATOLOGIC THERAPY (2022)

Get Full Text
Add to Collection

Journal

DERMATOLOGIC THERAPY
Volume 35, Issue 8, Pages -

Publisher

WILEY
DOI: 10.1111/dth.15634

Keywords

-

Categories

Dermatology

Funding

  1. Kyowa Kirin, Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.